PeriodontitisNCT04417478
Effect of Periodontal Debridement on Leptin Levels in Obese
A study testing Scaling and root planning in people with Periodontitis and Obesity, run by Universidad Nacional Andres Bello at 1 site in Chile.
Trial summary
The main purpose of the study is to quantify of Leptin hormone in patients with normal weight, class I obesity, class II obesity and periodontitis, before and after scaling and root planning (SRP) and correlate the Body mass index (BMI) with Leptin levels. A double-blind, controlled, clinical trial was conducted. Read more about this study
- Who is it for?
- Ages 25 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Periodontitis, Obesity
- What is being tested?
- Scaling and root planning
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteChile
- Study dates
- Dec 2016to Jul 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Patients ≥ 18 years.
- Patients classified by the American Society of Anesthesiologists (ASA) as ASA I or ASA II that are compatible with local anaesthesia procedures; - Present at least 10 natural teeth, excluding semi-erupted third molars.
- Present at least 6 sites with a probing depth (PD) ≥ 5mm and clinical attachment loss (CAL) ≥ 4mm.
- BMI between 18,50 - 39,99 kg/m2.
Who cannot join
- Patients with hemostasis disorders.
- Patients who use any medication associated with gingival disorders such as: Anticonvulsants (Phenytoin), Calcium channel blockers (Nifedipine), Immunosuppressive drugs (Cyclosporins).
- Patients with systemic diseases that affect the immunoinflammatory response.
- Patients under treatment with drugs such as: warfarin, digoxin and acetylsalicylic acid.
- Previous history of allergy to local anesthetics.
- Patients who suffer from systemic conditions that can affect the progression of periodontitis and/or the gain or loss of weight, for example:
Show all 14Show fewer
- Diabetes Mellitus, immunological disorders, hypothyroidism,etc.
- Patients who are under weight loss treatment (pharmacological, diet, exercise,etc).
- Patients presenting orthodontic appliances.
- Patients who have received antibiotic or periodontal treatment in the last 3 months.
- Pregnancy.
- Carriers of valvular prostheses or failures in heart valves, with endocarditis risk.
- Patients who are psychically and intellectually incapacitated to participate, according to the Chilean law number 20,584, title II, paragraph 8, article 28.
- Heavy smoking patients, which is smoking more than 10 cigarettes per day.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Periodontal Debridement on Leptin Levels in Patients With Class I and II Obesity With Periodontitis
The main purpose of the study is to quantify of Leptin hormone in patients with normal weight, class I obesity, class II obesity and periodontitis, before and after scaling and root planning (SRP) and correlate the Body mass index (BMI) with Leptin levels.
A double-blind, controlled, clinical trial was conducted. The sampling method was probabilistic stratified and the sample size 27 subjects in total, divided in 3 groups of: 9 normal weight patients, 9 class I Obesity patients and 9 class II Obesity patients and history of Generalized Periodontitis Stage II,III or IV, Grade B or C, who met the inclusion and exclusion criteria and signed an informed consent.
All patients received SRP and clinical monitoring at baseline and 3 months post-therapy by the same examiner.Probing depth (PD), Clinical Attachment Level (CAL), Biofilm Index (BI) and Bleeding on Probing (BoP), Tooth Mobility and Suppuration were evaluated as clinical variables. Serum levels of leptin were evaluated by enzyme-linked immunosorbent assay (ELISA) at baseline and 3 months post SRP.
Read the detailed description
Definition of the sample: 30 patients were recruited from the Diagnosis Unit of Andres Bello University Faculty of Dentistry (DUFD), campus Viña del Mar, with the diagnosis of Generalized Periodontitis Stage II, III or IV, grade B or C who were catalogued as normal weight, class I obesity and class II obesity who also fulfill the inclusion and exclusion criteria. Once the patients accepted the invitation to participate in the Investigative Project, they were given all the details and were requested to sign the Informed Consent form.
Sample Size Calculation:The minimum sample size necessary to validate the investigation is based on the study and results explained by Gonçalves, et al (2015), based on the variance of the differences of BMI of each classification. Considering the former data and using a significance level of 1%, a statistical power of 90% and an estimation error of 1, it was estimated a minimum of 12 patients for each group of normal weight, class I obesity and class II obesity. With the purpose of making a noticeable distinction between groups (class I and class II obesity) and without affecting the results of this study, there were considered 10 patients for each group of study.
Protocol and clinical exam: From the 30 initial patients at the beginning of the study, 27 was the number of patients who finally participated in it, as a result of 1 loss of tracing and 2 patients who interrupted their treatment. Two experimental groups were formed considering class I and class II obesity patients. The third group had control purposes and was composed by normal weight patients.
Presence or not of Obesity was determined by BMI, an indicator according to World Health Organization (WHO) which classifies adult population in several categories of weight using height and weight data. This information was measured and registered by only one examiner within the study. No compliance problems were noted and all patients followed the protocol of the study. None subjects reported specific adverse effects.
Type and design of study Randomized Clinical Trial. Sampling method: Probabilistic Stratified. Sample size: 27 subjects in total, divided in 3 groups of: 9 normal weight patients, 9 class I Obesity patients and 9 class II Obesity patients.
Standardization and calibration: In order to execute a properly standardized process, only instruments and supplies of the same commercial brand were used: periodontal diagnosis was always performed in a determined dental chair at the Dental Clinic of DUFD, under the same lighting system using a North Carolina Periodontal Probe (Hu-Friedy® Manufacturing Inc., Chicago,Illinois,USA). Only one examiner (FP) performed diagnosis and anthropometric measurements; these last ones were measured in a weight scale and measuring tape at the Dental Clinic of DUFD.
An inter-examiner calibration was necessary for diagnostic purposes and periodontal charting. This was performed between the only one examiner (FP) calibrated by the principal investigator (MN) according to a record set of calibration, which evaluated 2 sites in 4 teeth in a specific individual. This data was analysed according to Lin's Concordance Correlation Coefficient.
Anthropometric Measurements: An only one examiner inquired all measures of weight (Kg) and height (cm). BMI was calculated dividing weight by the height square. Patients were catalogued in a normal weight range when their BMI fluctuated between 18,50 y 24,99 kg/m2, Class I Obesity with a BMI between 30,00 a 34,99 kg/m2 and Class II Obesity with a BMI between 35,00 y 39,99 kg/m2, according to WHO.
Periodontal debridement: Patients were instructed according to Modified Bass Brushing Technique and were provided with the necessary items to do it properly (Dentaid® toothbrush, toothpaste and interdental brush). An exclusive examiner (IP) performed supragingival and subgingival debridement consistent in biofilm and dental calculus removal using an ultrasonic scaler (DTE®, Guilin Woodpecker Medical Instrument Co., Ltd., Guilin, Guangxi, P.R. China), followed by root scaling and planing in sites with Probing Depth ≥ 5mm and Clinical Attachment Level ≥ 4mm, using Gracey curettes (Hu-Friedy® Manufacturing Inc., Chicago, Illinois, USA). This treatment was performed to all patients taking 1-2 hours of work within 2- 4 maximum sessions. The procedures were performed under local anesthesia. Patients were called to a check-up at 3 months after treatment.
Clinical Evaluation : Patients went through a clinical evaluation at the beginning of treatment and after 3 months since therapy. The periodontal chart was completed using a North Carolina Periodontal Probe (Hu-Friedy® Manufacturing Inc., Chicago, Illinois, USA) measuring PD, CAL, presence of biofilm, bleeding on probing, suppuration and mobility.
Serum samples: All patients went through a blood sample collection consisting in the extraction of 4 millilitres of peripheral venous blood of the antecubital fascia of the arm with a 20-gauge needle and kept on stored in 6 millilitres serum Becton Dickinson (BD)Vacutainer® tubes. An hour after this process, the blood sample was centrifuged at 4000 revolutions per minute (rpm)for 10 minutes separating this way the rest of the components of the blood, which were distributed in aliquots and stored in -80 degree Celsius (ºC) for further analysis.
ELISA: One trained examiner (IP) analysed the serum samples by using the Leptin ELISA Kit (Thermo Fisher Scientific®., Massachusetts, USA). The trials were done according to manufacturer's instructions. This ELISA Kit is based on the "sandwich" technique for ELISA, it is to say, antibodies against a specific antigen coating the walls of the recipients of the ELISA kit. Since this kit works by immunoadsorption, the colour intensity of the product was directly proportional to the antigen concentration present in the sample. The optical density of the plate reader was adjusted to 450 mm. The results were measured as the concentration in milliliters of serum (pg/mL).
- Conditions
- Periodontitis, Obesity
- Being tested
- Scaling and root planning
- Keywords
- Obesity, Periodontal debridement, Periodontitis, Leptin, Body mass index
- Medical subject headings
- Periodontitis, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Scaling and root planningOther
Periodontal debridement was performed in all patients.
| Study group | Role | What they receive |
|---|---|---|
| Normal weight | Active comparator | Patients with Periodontitis and normal weight, that is BMI fluctuates between 18,50 y 24,99 kg/m2. Receives: Other: Scaling and root planning |
| class I Obesity | Experimental | Patients with Periodontitis and class I Obesity, that is BMI fluctuates between 30,00 a 34,99 kg/m2. Receives: Other: Scaling and root planning |
| class II Obesity | Experimental | Patients with Periodontitis and class II Obesity, that is BMI fluctuates between 35,00 y 39,99 kg/m2. Receives: Other: Scaling and root planning |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in serum levels of leptin at baseline and 3 month after SRP, in periodontal patients with normal weight, class I obesity and class II obesity.
Before and 3 month after performing SRP, serum levels of leptin was measured. All patients went through a blood sample collection consisting in the extraction of 4 milliliters of peripheral venous blood of the antecubital fossa of the arm with a 20-gauge needle and kept on stored in 6 milliliters serum Becton Dickinson (BD) Vacutainer® tubes. An hour after this process, the blood sample was centrifuged at 4000 rpm for 10 minutes separating this way the rest of the components of the blood, which were distributed in aliquots and stored in -80 degree Celsius (ºC) for further analysis. Later, the serum samples were analysed by using the Leptin ELISA Kit (Thermo Fisher Scientific®., Massachusetts, USA).
The results were measured as the concentration in millilitres of serum leptin (pg/ml).The student t test and ANOVA were applied to observe if there were significant differences between treatment groups.
Measured: Baseline and 3 month
Secondary outcomes (4)
Relation between serum levels of leptin and BMI of the periodontal patients, at baseline and 3 months after SRP.
Before and 3 months after performing SRP, serum levels of leptin were measured in the same way as described for the primary results.
BMI was calculated dividing weight by the height square. Patients were catalogued in a normal weight range when their BMI fluctuated between 18,50 y 24,99 kg/m2, Class I Obesity with a BMI between 30,00 a 34,99 kg/m2 and Class II Obesity with a BMI between 35,00 y 39,99 kg/m2, according to WHO. It was performed a correlation analysis using Kendall Tau test.
Measured: Baseline and 3 month
Number of sites with PD 1-3, 4-6 and ≥ 7mm and CAL ≥ 4 mm in periodontal patients obese and non obese, at baseline and 3 months after SRP.
PD corresponds to the distance in millimetres from the gingival margin (MG) to the inserted probe´s tip of the most apical portion of the periodontal pocket and CAL corresponds to the distance measured in millimetres from the cementum enamel junction to the tip of the probe inserted to the most apical portion of the periodontal pocket.Both were obtained by measuring with a North Carolina periodontal probe (Hu-Friedy® Manufacturing Inc., Chicago, Illinois, USA), in a position parallel to the vertical axis of the tooth, with a pressure no greater than 0.25 Newtons (N), in a circular direction over the entire surface of each tooth, registering the 6 deepest sites per tooth (mesiobuccal, buccal, distobuccal,distolingual, lingual and mesiolingual). Subsequently, those sites were counted and the student t test was applied to observe if there were significant differences between both treatment groups.
Measured: Baseline and 3 month.
Difference in the Biofilm Index (BI) in periodontal patients obese and non obese, at baseline and 3 months after SRP.
BI is percentage of dental surfaces with staining, through the use of biofilm developers. To obtain the index, a curaprox developer tablet was dissolved in a plastic cup with water and with a cotton ball this solution was applied on all of the tooth surfaces, recording only those that were stained. The calculation was made by dividing the surfaces that stained by the total surfaces, which corresponds to the number of teeth present multiplied by 4, and multiplying this value by 100. Subsequently, student t test was applied to observe if there were significant differences between treatment groups.
Measured: Baseline and 3 month.
Difference in Bleeding on Probing (BoP) index and Suppuration, in periodontal patients obese and non obese, at baseline and 3 months after SRP.
BoP is the percentage of sites that bleed when probing. Suppuration corresponds to the exit of purulent exudate by the crevice.
Both were recorded during PD measurement with a North Carolina periodontal probe (Hu-Friedy® Manufacturing Inc., Chicago, Illinois, USA) and was considered positive if it occurs 20 seconds after probing. The calculation was made by dividing the sites that bled or has suppuration by the total sites, which corresponds to the number of teeth present multiplied by 6, and multiplying this value by 100. Subsequently, student t test was applied to observe if there were significant differences between treatment groups.
Measured: Baseline and 3 month.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2020
- Study startDec 2016
- Primary completionJul 2019
- Study completionJul 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for PeriodontitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- A double-blind, controlled, clinical trial was conducted. The sampling method was probabilistic stratified and the sample size 27 subjects in total, divided in 3 groups of: 9 normal weight patients, 9 class I Obesity patients and 9 class II Obesity patients and history of moderate to severe periodontitis, who met the inclusion and exclusion criteria and signed an informed consent. All patients received SRP and clinical monitoring at baseline and 3 months post-therapy by the same examiner.Serum levels of leptin were evaluated by enzyme-linked immunosorbent assay at baseline and 3 months post SRP by one trained examiner.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 27 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidad Nacional Andres Bello
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mariely Navarrete, Universidad Nacional Andres Bello
- Investigators
- Mariely Navarrete Riffo, MSc, Principal investigator, Universidad Nacional Andres Bello
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04417478
- Sponsor's protocol ID
- 006
- Status last verified
- Jul 2020
- First submitted
- 1 Jun 2020
- Last updated
- 13 Jul 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Periodontol. 2018 Jun;89 Suppl 1:S159-S172. doi: 10.1002/JPER.18-0006.
PubMed 29926952Jain H, Mulay S. Relationship between periodontitis and systemic diseases: leptin, a new biomarker? Indian J Dent Res. 2014 Sep-Oct;25(5):657-61. doi: 10.4103/0970-9290.147118.
PubMed 25511069Papageorgiou SN, Reichert C, Jager A, Deschner J. Effect of overweight/obesity on response to periodontal treatment: systematic review and a meta-analysis. J Clin Periodontol. 2015 Mar;42(3):247-61. doi: 10.1111/jcpe.12365. Epub 2015 Feb 20.
PubMed 25580635Goncalves TE, Zimmermann GS, Figueiredo LC, Souza Mde C, da Cruz DF, Bastos MF, da Silva HD, Duarte PM. Local and serum levels of adipokines in patients with obesity after periodontal therapy: one-year follow-up. J Clin Periodontol. 2015 May;42(5):431-9. doi: 10.1111/jcpe.12396. Epub 2015 Apr 30.
PubMed 25858047
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Periodontal Debridement on Leptin Levels in Patients With Class I and II Obesity With Periodontitis
- ClinicalTrials.gov ID
- NCT04417478
- Acronym / sponsor ID
- 006
- Conditions
- Periodontitis, Obesity
- Keywords
- Obesity, Periodontal debridement, Periodontitis, Leptin, Body mass index
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 27 participants (actual)
- Lead sponsor
- Universidad Nacional Andres BelloUniversity, hospital or other
- Study start
- Dec 2016 (actual)
- Primary completion
- Jul 2019 (actual)
- Study completion
- Jul 2019 (actual)
- First posted
- 4 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main purpose of the study is to quantify of Leptin hormone in patients with normal weight, class I obesity, class II obesity and periodontitis, before and after scaling and root planning (SRP) and correlate the Body mass index (BMI) with Leptin levels.
A double-blind, controlled, clinical trial was conducted. The sampling method was probabilistic stratified and the sample size 27 subjects in total, divided in 3 groups of: 9 normal weight patients, 9 class I Obesity patients and 9 class II Obesity patients and history of Generalized Periodontitis Stage II,III or IV, Grade B or C, who met the inclusion and exclusion criteria and signed an informed consent.
All patients received SRP and clinical monitoring at baseline and 3 months post-therapy by the same examiner.Probing depth (PD), Clinical Attachment Level (CAL), Biofilm Index (BI) and Bleeding on Probing (BoP), Tooth Mobility and Suppuration were evaluated as clinical variables. Serum levels of leptin were evaluated by enzyme-linked immunosorbent assay (ELISA) at baseline and 3 months post SRP.
Detailed description
Definition of the sample: 30 patients were recruited from the Diagnosis Unit of Andres Bello University Faculty of Dentistry (DUFD), campus Viña del Mar, with the diagnosis of Generalized Periodontitis Stage II, III or IV, grade B or C who were catalogued as normal weight, class I obesity and class II obesity who also fulfill the inclusion and exclusion criteria. Once the patients accepted the invitation to participate in the Investigative Project, they were given all the details and were requested to sign the Informed Consent form.
Sample Size Calculation:The minimum sample size necessary to validate the investigation is based on the study and results explained by Gonçalves, et al (2015), based on the variance of the differences of BMI of each classification. Considering the former data and using a significance level of 1%, a statistical power of 90% and an estimation error of 1, it was estimated a minimum of 12 patients for each group of normal weight, class I obesity and class II obesity. With the purpose of making a noticeable distinction between groups (class I and class II obesity) and without affecting the results of this study, there were considered 10 patients for each group of study.
Protocol and clinical exam: From the 30 initial patients at the beginning of the study, 27 was the number of patients who finally participated in it, as a result of 1 loss of tracing and 2 patients who interrupted their treatment. Two experimental groups were formed considering class I and class II obesity patients. The third group had control purposes and was composed by normal weight patients.
Presence or not of Obesity was determined by BMI, an indicator according to World Health Organization (WHO) which classifies adult population in several categories of weight using height and weight data. This information was measured and registered by only one examiner within the study. No compliance problems were noted and all patients followed the protocol of the study. None subjects reported specific adverse effects.
Type and design of study Randomized Clinical Trial. Sampling method: Probabilistic Stratified. Sample size: 27 subjects in total, divided in 3 groups of: 9 normal weight patients, 9 class I Obesity patients and 9 class II Obesity patients.
Standardization and calibration: In order to execute a properly standardized process, only instruments and supplies of the same commercial brand were used: periodontal diagnosis was always performed in a determined dental chair at the Dental Clinic of DUFD, under the same lighting system using a North Carolina Periodontal Probe (Hu-Friedy® Manufacturing Inc., Chicago,Illinois,USA). Only one examiner (FP) performed diagnosis and anthropometric measurements; these last ones were measured in a weight scale and measuring tape at the Dental Clinic of DUFD.
An inter-examiner calibration was necessary for diagnostic purposes and periodontal charting. This was performed between the only one examiner (FP) calibrated by the principal investigator (MN) according to a record set of calibration, which evaluated 2 sites in 4 teeth in a specific individual. This data was analysed according to Lin's Concordance Correlation Coefficient.
Anthropometric Measurements: An only one examiner inquired all measures of weight (Kg) and height (cm). BMI was calculated dividing weight by the height square. Patients were catalogued in a normal weight range when their BMI fluctuated between 18,50 y 24,99 kg/m2, Class I Obesity with a BMI between 30,00 a 34,99 kg/m2 and Class II Obesity with a BMI between 35,00 y 39,99 kg/m2, according to WHO.
Periodontal debridement: Patients were instructed according to Modified Bass Brushing Technique and were provided with the necessary items to do it properly (Dentaid® toothbrush, toothpaste and interdental brush). An exclusive examiner (IP) performed supragingival and subgingival debridement consistent in biofilm and dental calculus removal using an ultrasonic scaler (DTE®, Guilin Woodpecker Medical Instrument Co., Ltd., Guilin, Guangxi, P.R. China), followed by root scaling and planing in sites with Probing Depth ≥ 5mm and Clinical Attachment Level ≥ 4mm, using Gracey curettes (Hu-Friedy® Manufacturing Inc., Chicago, Illinois, USA). This treatment was performed to all patients taking 1-2 hours of work within 2- 4 maximum sessions. The procedures were performed under local anesthesia. Patients were called to a check-up at 3 months after treatment.
Clinical Evaluation : Patients went through a clinical evaluation at the beginning of treatment and after 3 months since therapy. The periodontal chart was completed using a North Carolina Periodontal Probe (Hu-Friedy® Manufacturing Inc., Chicago, Illinois, USA) measuring PD, CAL, presence of biofilm, bleeding on probing, suppuration and mobility.
Serum samples: All patients went through a blood sample collection consisting in the extraction of 4 millilitres of peripheral venous blood of the antecubital fascia of the arm with a 20-gauge needle and kept on stored in 6 millilitres serum Becton Dickinson (BD)Vacutainer® tubes. An hour after this process, the blood sample was centrifuged at 4000 revolutions per minute (rpm)for 10 minutes separating this way the rest of the components of the blood, which were distributed in aliquots and stored in -80 degree Celsius (ºC) for further analysis.
ELISA: One trained examiner (IP) analysed the serum samples by using the Leptin ELISA Kit (Thermo Fisher Scientific®., Massachusetts, USA). The trials were done according to manufacturer's instructions. This ELISA Kit is based on the "sandwich" technique for ELISA, it is to say, antibodies against a specific antigen coating the walls of the recipients of the ELISA kit. Since this kit works by immunoadsorption, the colour intensity of the product was directly proportional to the antigen concentration present in the sample. The optical density of the plate reader was adjusted to 450 mm. The results were measured as the concentration in milliliters of serum (pg/mL).
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 3
- Model description
- A double-blind, controlled, clinical trial was conducted. The sampling method was probabilistic stratified and the sample size 27 subjects in total, divided in 3 groups of: 9 normal weight patients, 9 class I Obesity patients and 9 class II Obesity patients and history of moderate to severe periodontitis, who met the inclusion and exclusion criteria and signed an informed consent. All patients received SRP and clinical monitoring at baseline and 3 months post-therapy by the same examiner.Serum levels of leptin were evaluated by enzyme-linked immunosorbent assay at baseline and 3 months post SRP by one trained examiner.
| Arm | Type | Receives |
|---|---|---|
| Normal weight | Active comparator | Other: Scaling and root planningPatients with Periodontitis and normal weight, that is BMI fluctuates between 18,50 y 24,99 kg/m2. |
| class I Obesity | Experimental | Other: Scaling and root planningPatients with Periodontitis and class I Obesity, that is BMI fluctuates between 30,00 a 34,99 kg/m2. |
| class II Obesity | Experimental | Other: Scaling and root planningPatients with Periodontitis and class II Obesity, that is BMI fluctuates between 35,00 y 39,99 kg/m2. |
Who may qualify
- Ages
- 25 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients ≥ 18 years.
- Patients classified by the American Society of Anesthesiologists (ASA) as ASA I or ASA II that are compatible with local anaesthesia procedures; - Present at least 10 natural teeth, excluding semi-erupted third molars.
- Present at least 6 sites with a probing depth (PD) ≥ 5mm and clinical attachment loss (CAL) ≥ 4mm.
- BMI between 18,50 - 39,99 kg/m2.
Key exclusion criteria (14 listed)
- Patients with hemostasis disorders.
- Patients who use any medication associated with gingival disorders such as: Anticonvulsants (Phenytoin), Calcium channel blockers (Nifedipine), Immunosuppressive drugs (Cyclosporins).
- Patients with systemic diseases that affect the immunoinflammatory response.
- Patients under treatment with drugs such as: warfarin, digoxin and acetylsalicylic acid.
- Previous history of allergy to local anesthetics.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Scaling and root planningPeriodontal debridement was performed in all patients. | Other | Normal weight, class I Obesity, class II Obesity |
Primary outcome
Difference in serum levels of leptin at baseline and 3 month after SRP, in periodontal patients with normal weight, class I obesity and class II obesity.
Time frame: Baseline and 3 month
Before and 3 month after performing SRP, serum levels of leptin was measured. All patients went through a blood sample collection consisting in the extraction of 4 milliliters of peripheral venous blood of the antecubital fossa of the arm with a 20-gauge needle and kept on stored in 6 milliliters serum Becton Dickinson (BD) Vacutainer® tubes. An hour after this process, the blood sample was centrifuged at 4000 rpm for 10 minutes separating this way the rest of the components of the blood, which were distributed in aliquots and stored in -80 degree Celsius (ºC) for further analysis. Later, the serum samples were analysed by using the Leptin ELISA Kit (Thermo Fisher Scientific®., Massachusetts, USA). The results were measured as the concentration in millilitres of serum leptin (pg/ml).The student t test and ANOVA were applied to observe if there were significant differences between treatment groups.
4 secondary outcomes
Relation between serum levels of leptin and BMI of the periodontal patients, at baseline and 3 months after SRP.
Time frame: Baseline and 3 month
Number of sites with PD 1-3, 4-6 and ≥ 7mm and CAL ≥ 4 mm in periodontal patients obese and non obese, at baseline and 3 months after SRP.
Time frame: Baseline and 3 month.
Difference in the Biofilm Index (BI) in periodontal patients obese and non obese, at baseline and 3 months after SRP.
Time frame: Baseline and 3 month.
Difference in Bleeding on Probing (BoP) index and Suppuration, in periodontal patients obese and non obese, at baseline and 3 months after SRP.
Time frame: Baseline and 3 month.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2020.
- Background: PubMed 29926952Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Periodontol. 2018 Jun;89 Suppl 1:S159-S172. doi: 10.1002/JPER.18-0006.
- Background: PubMed 25511069Jain H, Mulay S. Relationship between periodontitis and systemic diseases: leptin, a new biomarker? Indian J Dent Res. 2014 Sep-Oct;25(5):657-61. doi: 10.4103/0970-9290.147118.
- Background: PubMed 25580635Papageorgiou SN, Reichert C, Jager A, Deschner J. Effect of overweight/obesity on response to periodontal treatment: systematic review and a meta-analysis. J Clin Periodontol. 2015 Mar;42(3):247-61. doi: 10.1111/jcpe.12365. Epub 2015 Feb 20.
- Results publication: PubMed 25858047Goncalves TE, Zimmermann GS, Figueiredo LC, Souza Mde C, da Cruz DF, Bastos MF, da Silva HD, Duarte PM. Local and serum levels of adipokines in patients with obesity after periodontal therapy: one-year follow-up. J Clin Periodontol. 2015 May;42(5):431-9. doi: 10.1111/jcpe.12396. Epub 2015 Apr 30.
- Individual participant dataSharing planned: No
Related trials for Periodontitis
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Probiotics Versus Antibiotics as an Adjuvant to Non-surgical Periodontal Treatment Among Smokers With Stage II, Grade B Periodontitis
Probiotics, Antibiotics
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mariely Navarrete Riffo, MSc principal investigator
Universidad Nacional Andres Bello
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Scaling and root planning in people with Periodontitis and Obesity, run by Universidad Nacional Andres Bello at 1 site in Chile.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in serum levels of leptin at baseline and 3 month after SRP, in periodontal patients with normal weight, class I obesity and class II obesity. (time frame: Baseline and 3 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04417478, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2020.